D C Montefiori

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint HIV vaccine development at Duke University Medical Center
    B F Haynes
    Department of Medicine, The Duke Center for Aids Research, Duke University Medical Center, Durham, NC 27710, USA
    Immunol Res 22:263-9. 2000
  2. pmc Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously
    Jennifer L Greenier
    California National Primate Research Center, University of California, Davis, CA 95616, USA
    Virol J 2:11. 2005
  3. pmc Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques
    D C Montefiori
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 75:5879-90. 2001
  4. ncbi request reprint Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines
    David C Montefiori
    Department of Surgery, Laboratory for AIDS Vaccine Research and Development, Duke University Medical Center, PO Box 2926, Durham, NC 27710, USA
    J Infect Dis 190:1962-9. 2004
  5. ncbi request reprint Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual
    David C Montefiori
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 170:3906-14. 2003
  6. pmc Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage
    D C Montefiori
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Virol 72:1886-93. 1998
  7. pmc Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains
    H X Liao
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Virol 74:254-63. 2000
  8. pmc Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection
    D C Montefiori
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Virol 75:10200-7. 2001
  9. pmc Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1
    D C Montefiori
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Virol 72:3427-31. 1998
  10. ncbi request reprint Linkage of the CCR5 Delta 32 mutation with a functional polymorphism of CD45RA
    H X Liao
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 165:148-57. 2000

Research Grants

  1. HIV Vaccine Development
    David Montefiori; Fiscal Year: 2003

Detail Information

Publications71

  1. ncbi request reprint HIV vaccine development at Duke University Medical Center
    B F Haynes
    Department of Medicine, The Duke Center for Aids Research, Duke University Medical Center, Durham, NC 27710, USA
    Immunol Res 22:263-9. 2000
    ..This brief review summarizes ongoing work at the Duke University School of Medicine on HIV vaccine development...
  2. pmc Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously
    Jennifer L Greenier
    California National Primate Research Center, University of California, Davis, CA 95616, USA
    Virol J 2:11. 2005
    ..J. Virology 77:179-190, 2003). Here we evaluate the impact of these vaccines on oral transmission and evolution of SIV envelope variants...
  3. pmc Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques
    D C Montefiori
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 75:5879-90. 2001
    ..The results demonstrate the feasibility of generating neutralizing antibodies and cellular immune responses that target an R5 primary HIV-1 isolate by vaccination in primates...
  4. ncbi request reprint Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines
    David C Montefiori
    Department of Surgery, Laboratory for AIDS Vaccine Research and Development, Duke University Medical Center, PO Box 2926, Durham, NC 27710, USA
    J Infect Dis 190:1962-9. 2004
    ..These data indicate that race may affect the neutralizing antibody response to some gp120 immunogens. To fully evaluate immunogenicity, clinical trials of candidate vaccines should enroll diverse populations of subjects...
  5. ncbi request reprint Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual
    David C Montefiori
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 170:3906-14. 2003
    ..We postulate that an early effective neutralizing Ab response can provide long-term clinical benefits despite neutralization escape...
  6. pmc Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage
    D C Montefiori
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Virol 72:1886-93. 1998
    ..The results indicate that the ability of HIV-1 to be neutralized by sera from infected individuals depends on factors other than coreceptor usage...
  7. pmc Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains
    H X Liao
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Virol 74:254-63. 2000
    ..6. In contrast to natural infection with SHIV-89.6, in which few animals make anti-V3 antibodies, C4-V3 peptides frequently induced anti-V3 antibodies that neutralized primary isolate SHIV strains...
  8. pmc Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection
    D C Montefiori
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Virol 75:10200-7. 2001
    ....
  9. pmc Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1
    D C Montefiori
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Virol 72:3427-31. 1998
    ..6, and SHIV-89.6P possess highly divergent, strain-specific neutralization epitopes. The results also provide insights into the requirements for raising neutralizing antibodies to primary isolates of HIV-1...
  10. ncbi request reprint Linkage of the CCR5 Delta 32 mutation with a functional polymorphism of CD45RA
    H X Liao
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 165:148-57. 2000
    ..w. CD45RA isoforms. Although the presence of the CCR5 Delta 32 mutation down-regulates HIV-1 infection of thymocytes, the functional CD45RA polymorphism does not alter the susceptibility of thymocytes to HIV-1 infection in vitro...
  11. pmc HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life
    N L Yates
    Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA
    Mucosal Immunol 6:692-703. 2013
    ..HIV-1 transmission frequently elicits mucosal HIV-1 envelope-specific IgA responses targeted to gp41 that have a short half-life...
  12. ncbi request reprint Short communication: characteristics of effective immune control of simian/human immunodeficiency virus in pigtail macaques
    Ivan Stratov
    Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria 3010, Australia
    AIDS Res Hum Retroviruses 22:27-32. 2006
    ..These observations, although in a small subset of animals, suggest the hypothesis that combinations of primed T cell immunity and neutralizing antibodies can maintain control of chronic primate lentiviral infections...
  13. pmc Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques
    Jörn E Schmitz
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, RE 113, 330 Brookline Ave, Boston, Massacusetts 02215, USA
    J Virol 79:8131-41. 2005
    ....
  14. pmc Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial
    Nina D Russell
    Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Acquir Immune Defic Syndr 44:203-12. 2007
    ..We conducted a phase 2 trial to determine if a canarypox vaccine candidate (vCP1452) administered with rgp120 subunit protein would "qualify" for a trial to define a correlate of efficacy...
  15. ncbi request reprint Single epitope mucosal vaccine delivered via immuno-stimulating complexes induces low level of immunity against simian-HIV
    Bapi Pahar
    Tulane National Primate Research Center, Covington, LA 70433, USA
    Vaccine 24:6839-49. 2006
    ..We predict that if coadministered with additional epitopes and/or more efficacious mucosal delivery system or route, HIV/SIV-derived peptide vaccines may have potential to elicit heterologous protection...
  16. pmc Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies
    Ming Li
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 79:10108-25. 2005
    ..These reference reagents will facilitate proficiency testing and other validation efforts aimed at improving assay performance across laboratories and can be used for standardized assessments of vaccine-elicited neutralizing antibodies...
  17. pmc A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA
    Virology 353:268-82. 2006
    ..Our study also shows the feasibility of iterative improvements in Env immunogenicity by rational design of centralized genes...
  18. ncbi request reprint Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates
    Barton F Haynes
    Duke University Medical Center, Durham, NC 27710, USA
    Expert Rev Vaccines 5:579-95. 2006
    ....
  19. pmc Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa
    Ming Li
    Department of Surgery, Laboratory for AIDS Vaccine Research and Development, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 80:11776-90. 2006
    ..A subset of these gp160 clones are suitable for use as reference reagents to facilitate standardized assessments of vaccine-elicited neutralizing antibody responses...
  20. ncbi request reprint High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects
    Paul A Goepfert
    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294 2050, USA
    J Infect Dis 192:1249-59. 2005
    ..0) TCID50 (60 participants) than when given at the regular dose, 10(7.26) TCID50 (40 participants); as a control, a placebo vaccine preparation also was administered (10 participants)...
  21. ncbi request reprint An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains
    V Rául Gómez-Román
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 5065, USA
    J Acquir Immune Defic Syndr 43:270-7. 2006
    ..Incorporating additional non-subtype B envelope genes and protein boosts in a multivalent strategy may be required to elicit broader neutralizing antibodies against non-subtype B HIV strains...
  22. ncbi request reprint Comparative evaluation of simian, simian-human, and human immunodeficiency virus infections in the pigtail macaque (Macaca nemestrina) model
    C Jane Batten
    Department of Microbiology and Immunology, University of Melbourne, Victoria 3010, Australia
    AIDS Res Hum Retroviruses 22:580-8. 2006
    ..Our results provide a series of virologic models with which to evaluate potential AIDS vaccines in pigtail macaques...
  23. ncbi request reprint Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine
    Harriet L Robinson
    Emory Vaccine Center of Emory University School of Medicine, Atlanta, GA 30322, USA
    Virology 352:285-94. 2006
    ..The GM-CSF-adjuvanted group showed a trend towards better control of the challenge infection and had better control of re-emergent virus (P < 0.01) than the non-adjuvanted group...
  24. ncbi request reprint Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques
    Siew Yen Chong
    Wyeth Vaccines Discovery, 401 N Middletown Road, Pearl River, NY 10965, USA
    Vaccine 25:4967-82. 2007
    ..These results have important implications for the continued development of plasmid DNA vaccines for the prevention of HIV-1 infection...
  25. pmc A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120
    Emma T Crooks
    Torrey Pines Institute for Molecular Studies, 3550 General Atomics Court, San Diego, CA 92121, USA
    Virology 366:245-62. 2007
    ..Therefore, to make progress toward a more effective VLP-based vaccine, we will need to find ways to refocus the attention of B cells on native trimers...
  26. pmc Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies
    Vidita Choudhry
    Protein Interactions Group, CCRNP, NCI Frederick, NIH, Frederick, MD 21702, USA
    Virology 363:79-90. 2007
    ....
  27. pmc Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers
    Shixia Wang
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Vaccine 26:3947-57. 2008
    ....
  28. pmc Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination
    Michael Vaine
    Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
    J Virol 82:7369-78. 2008
    ....
  29. pmc Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens
    Mei Yun Zhang
    CCRNP, CCR, NCI Frederick, NIH, Bldg 469, Rm 131, P O Box B, Miller Drive, Frederick, MD 21702 1201, USA
    J Virol 82:6869-79. 2008
    ..Its novel conserved conformational epitope on gp41 could be helpful in the design of vaccine immunogens and as a target for therapeutics...
  30. pmc Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes
    Nobuyuki Matoba
    Center for Infectious Diseases and Vaccinology, The Biodesign Institute and School of Life Sciences, Arizona State University, Tempe, AZ 85287 4501, USA
    Curr HIV Res 6:218-29. 2008
    ..We propose that Abs induced by MPR(649-684)-based immunogens may provide broad protective value independent of infection neutralization...
  31. doi request reprint Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays
    David C Montefiori
    Duke University Medical Center, Durham, North Carolina, USA
    Curr Protoc Immunol . 2005
    ..Both assays are performed in a 96-well format and use tat-responsive luciferase reporter gene expression as readout...
  32. doi request reprint Analysis of the immune responses in chimpanzees infected with HIV type 1 isolates
    Laure Y Juompan
    Yerkes National Primate Research Center and Department of Microbiology, Emory University, Atlanta, Georgia 30329, USA
    AIDS Res Hum Retroviruses 24:573-86. 2008
    ..Taken together, pathogenic HIV infection in chimpanzees is associated with rapid loss of CD4(+) T cells and proliferative responses as well as higher levels of immune activation...
  33. doi request reprint Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination
    Victoria R Polonis
    Walter Reed Army Institute of Research, Washington, DC, USA
    Virology 375:315-20. 2008
    ....
  34. doi request reprint Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates
    Anna U Bielinska
    Michigan Nanotechnology Institute for Medicine and Biological Sciences MNIMBS, University of Michigan, Ann Arbor, Michigan 48109, USA
    AIDS Res Hum Retroviruses 24:271-81. 2008
    ..This study suggests that NE should be evaluated as a mucosal adjuvant for multivalent HIV vaccines...
  35. doi request reprint Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques
    L Jean Patterson
    Vaccine Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Virology 374:322-37. 2008
    ..Macaques not boosted, showed a significant reduction in set point viremia, a full 32 weeks after the last Ad priming immunization. The HIV peptomer-boosted group showed a trend toward chronic viremia reduction, but was not protected...
  36. pmc Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope
    Adam Penn-Nicholson
    Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
    Virology 372:442-56. 2008
    ..These soluble gp41 fusion proteins could be an important source of antigens for future vaccine development efforts...
  37. pmc Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection
    S Munir Alam
    Human Vaccine Institute, Box 3258, Duke University Medical Center, MSRBII Bldg, Room 4042, Durham, NC 27710, USA
    J Virol 82:115-25. 2008
    ....
  38. ncbi request reprint Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120
    Farley Cleghorn
    Center for HIV AIDS, Constella Futures, Washington, DC, USA
    J Acquir Immune Defic Syndr 46:222-30. 2007
    ..vCP1452 was administered alone or with a heterologous boost of MN rgp120 glycoprotein. The trial was pivotal in deciding whether these vaccines advanced to phase 3 efficacy trials...
  39. pmc Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens
    Michael S Seaman
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, 330 Brookline Ave RE 204, Boston, MA 02215, USA
    Virology 367:175-86. 2007
    ....
  40. ncbi request reprint Neutralizing antibodies take a swipe at HIV in vivo
    David C Montefiori
    Nat Med 11:593-4. 2005
  41. pmc Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1
    Shixia Wang
    Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Lazare Research Building, Worcester, MA 01605 2397, USA
    J Virol 79:7933-7. 2005
    ....
  42. ncbi request reprint Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate
    Bimal K Chakrabarti
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, MD 20892 3005, USA
    Vaccine 23:3434-45. 2005
    ..These studies suggest that combinations of Env immunogens, despite the limited reactivity of the V3 from each component, can be used to expand the breadth of the neutralizing antibody response...
  43. pmc Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d
    Thomas D Green
    Department of Microbiology and Immunology, East Carolina University School of Medicine, Greenville, North Carolina 27858, USA
    J Virol 77:2046-55. 2003
    ....
  44. ncbi request reprint HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus
    Marcus Altfeld
    Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital and Division of AIDS, Harvard Medical School, Boston, Massachusetts 02129, USA
    Nature 420:434-9. 2002
    ..The lack of cross-protective immunity for closely related HIV-1 strains, despite persistent recognition of multiple CD8 epitopes, has important implications for public health and vaccine development...
  45. ncbi request reprint Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses
    Zdenek Hel
    Basic Research Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 169:4778-87. 2002
    ..The results presented in this work also further demonstrate the potential of a DNA-prime/attenuated poxvirus-boost vaccine regimen in an animal model that well mirrors human AIDS...
  46. pmc Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251
    Barbara L Shacklett
    Gladstone Institute of Virology and Immunology, University of California San Francisco, San Francisco 94141 9100, USA
    J Virol 76:11365-78. 2002
    ..These findings demonstrate that SIVmac-M4, which contains a full-length Nef coding region and multiple point mutations in the TM, can provide substantial protection from mucosal challenge with pathogenic SIVmac251...
  47. pmc Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer
    Anne D Lewis
    Columbus Children s Research Institute, Children s Hospital, Department of Pediatrics, College of Medicine and Public Health, The Ohio State University, Columbus, Ohio, USA
    J Virol 76:8769-75. 2002
    ..This approach allows for predetermination of antibody affinity and specificity prior to "immunization" and avoids the need for an active humoral immune response against the HIV envelope protein...
  48. pmc Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines
    Rama Rao Amara
    Vaccine Research Center and Yerkes Regional Primate Research Center, Emory University, Atlanta, Georgia 30329, USA
    J Virol 76:7625-31. 2002
    ..Thus, MVA vaccines, as well as DNA/MVA vaccines, merit further evaluation for their ability to control the current AIDS pandemic...
  49. pmc Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression follow
    Helen Horton
    Wisconsin Regional Primate Research Center, University of Wisconsin, Madison, Wisconsin 53715, USA
    J Virol 76:7187-202. 2002
    ..01). However, despite the induction of virus-specific cellular immune responses and reduced peak viral loads, most animals still suffered from gradual CD4 depletion and progressed to disease...
  50. pmc Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine
    Rama Rao Amara
    Vaccine Research Center, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    J Virol 76:6138-46. 2002
    ..Our results highlight the importance of immune responses to Env, as well as to Gag-Pol, in the control of immunodeficiency virus challenges and the protection of CD4(+) cells...
  51. pmc Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization
    Bimal K Chakrabarti
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 3005, USA
    J Virol 76:5357-68. 2002
    ..Importantly, this modified Env, gp140 Delta CFI, stimulated the antibody response to native gp160 while it retained its ability to induce a CTL response, a desirable feature for an AIDS vaccine...
  52. ncbi request reprint Neutralizing antibodies as a potential secondary protective mechanism during chronic SHIV infection in CD8+ T-cell-depleted macaques
    Robert A Rasmussen
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    AIDS 16:829-38. 2002
    ..To directly examine the role of CD8+ T cells in controlling viremia and disease during chronic, low-level primate immunodeficiency virus infection in DNA prime/protein boost-vaccinated macaques...
  53. ncbi request reprint Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A
    Kalpana Gupta
    Department of Medicine, University of Washington, Seattle, Washington, USA
    J Acquir Immune Defic Syndr 29:254-61. 2002
    ..This high-titered preparation of ALVAC-HIV vCP205 in combination with gp120 was safe and immunogenic in a diverse group of HIV-1-seronegative volunteers...
  54. pmc Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa
    Renata Bures
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 76:2233-44. 2002
    ..The clustering of shared neutralization determinants on clade C primary HIV-1 isolates from South Africa suggests that neutralizing antibodies induced by vaccines will have less epitope diversity to overcome at a regional level...
  55. ncbi request reprint Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes
    Dan H Barouch
    Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Research East Room 113, 330 Brookline Avenue, Boston, Massachusetts 02215, USA
    Nature 415:335-9. 2002
    ..These data indicate that viral escape from CTL recognition may be a major limitation of the CTL-based AIDS vaccines that are likely to be administered to large human populations over the next several years...
  56. ncbi request reprint HIV-1: nature's master of disguise
    John R Mascola
    Nat Med 9:393-4. 2003
  57. ncbi request reprint Evidence for immune-mediated reduction of viral replication in Macaca nemestrina mucosally immunized with inactivated SHIV(89.6)
    Zandrea Ambrose
    Department of Pathobiology, School of Public Health and Community Medicine, University of Washington, Seattle, WA 98195, USA
    Virology 308:178-90. 2003
    ..These data suggest that cellular immunity was required for protection from intravaginal challenge. This immunization regimen provides a promising lead for vaccine development...
  58. ncbi request reprint HIV-1 neutralization by chimeric CD4-CG10 polypeptides fused to human IgG1
    Ronit Meyuhas
    Laboratory of Immunology, Migal Galilee Technology Center, P O Box 831, Kiryat Shmona 11016, Israel
    Mol Immunol 42:1099-109. 2005
    ..Our findings underscore the potential use of CD4-based fusion proteins in the design of HIV immuno-therapeutics...
  59. pmc Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells
    Gerald V Quinnan
    Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd, Bethesda, MD 20814, USA
    J Virol 79:3358-69. 2005
    ..Induction of cross-reactive, primary HIV-1-neutralizing antibodies is feasible and, when potent, may result in complete protection against infection with a heterologous challenge virus strain...
  60. pmc Signature for long-term vaccine-mediated control of a Simian and human immunodeficiency virus 89.6P challenge: stable low-breadth and low-frequency T-cell response capable of coproducing gamma interferon and interleukin-2
    Shanmugalakshmi Sadagopal
    Yerkes National Primate Research Center of Emory University, 954 Gatewood Dr, Atlanta, GA 30329, USA
    J Virol 79:3243-53. 2005
    ..Overall, high titers of binding and neutralizing antibody persisted throughout the postchallenge period. Encouragingly, long-term control was effective in macaques of diverse histocompatibility types...
  61. pmc Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys
    Norman L Letvin
    Vaccine Research Center, National Institutes of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland 20892 3005, USA
    J Virol 78:7490-7. 2004
    ....
  62. ncbi request reprint Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies
    Mikyung Kim
    Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    AIDS Res Hum Retroviruses 21:58-67. 2005
    ..This ADAgp140 immunogen may be considered a starting point from which to engineer additional improvements for cross-reactive neutralizing antibody induction...
  63. ncbi request reprint Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes
    Michael A Egan
    Wyeth Vaccines Research, Pearl River, New York 10965, USA
    AIDS Res Hum Retroviruses 20:989-1004. 2004
    ....
  64. pmc Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque
    Philip M McKenna
    Department of Microbiology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA
    J Virol 78:13455-9. 2004
    ..6P). There was no evidence of CD4(+) T-cell loss, and plasma viremia was controlled to undetectable levels by 6 weeks postchallenge and has remained suppressed out to 22 weeks postchallenge...
  65. ncbi request reprint A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques
    Michael A Egan
    Wyeth Vaccines Research, Pearl River, NY 10965, USA
    Vaccine 22:3774-88. 2004
    ..These results suggest that parenteral vaccine administration in combination with the appropriate adjuvant formulation can elicit vaccine-specific humoral immune responses in both systemic and mucosal compartments...
  66. pmc Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody
    Mei Yun Zhang
    Human Immunovirology Group, Laboratory of Experimental and Computational Biology, Center for Cancer Research, National Cancer Institute Frederick, NIH, Frederick, Maryland 21702 1201, USA
    J Virol 78:9233-42. 2004
    ....
  67. ncbi request reprint Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component
    Linda S Wyatt
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    AIDS Res Hum Retroviruses 20:645-53. 2004
    ..In the accompanying paper, we show that MVA/HIV 48 provided efficient boosting of an HIV DNA vaccine...
  68. ncbi request reprint Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies
    Flavia Ferrantelli
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Infect Dis 189:2167-73. 2004
    ..These data are important for designing clinical trials in human neonates and have general implications for AIDS vaccine development, as the epitopes recognized by the 3 nMAbs are conserved among diverse primary isolates...
  69. pmc Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins
    Hua Xin Liao
    Duke Human Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
    J Virol 78:5270-8. 2004
    ....
  70. pmc Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies
    John R Mascola
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:10348-56. 2003
    ..These data suggest that although effector T cells can limit viral replication, they are not able to assist humoral immunity to prevent the establishment of initial infection...
  71. ncbi request reprint Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
    John W Shiver
    Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    Nature 415:331-5. 2002
    ..The replication-defective adenovirus is a promising vaccine vector for development of an HIV-1 vaccine...

Research Grants1

  1. HIV Vaccine Development
    David Montefiori; Fiscal Year: 2003
    ....